THYROID CANCERS
Latest News
November 11th 2024
During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.
September 27th 2024
September 24th 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
More News
LOXO-292 Induces 77% ORR in RET-Positive Tumors
June 2nd 2018The highly-selective RET inhibitor LOXO-292 induced an objective response rate of 77% for patients with RET fusion-positive non–small cell lung cancer, according to findings from the phase I LIBRETTO-001 study presented at the 2018 ASCO Annual Meeting.
Read More
Dabrafenib/Trametinib Combo Approved by FDA for BRAF+ Thyroid Cancer
May 4th 2018The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has been approved by the FDA for the treatment of patients with unresectable or metastatic<em> BRAF</em> V600E–positive anaplastic thyroid cancer.
Read More
